16 Sep 2003

The scientist who helped discover one of the few drugs currently approved for the treatment of Alzheimer's disease has received the $100,000 Alzheimer's Drug Discovery Award for 2003. Marta Weinstock and colleagues at the Hebrew University of Jerusalem helped develop rivastigmine, an acetylcholinesterase inhibitor that is now marketed worldwide by Novartis Pharmaceuticals under the trade name Exelon. The award is funded by Anne and Howard Gottlieb and the New York-based Institute for the Study of Aging, a biomedical venture philanthropy whose mission is to catalyze and fund the discovery and development of new therapies to prevent and treat cognitive aging and Alzheimer’s disease.

For more information, see http://biz.yahoo.com/prnews/030916/nytu023_1.html